ETTX
$2.50
Entasis Therapeutics Holdings
($.11)
(4.21%)
ETTX
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  ($0.24)
Revenue:  N/A
Thursday
Aug 5
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ETTX reports earnings?
Beat
Meet
Miss

Where is ETTX's stock price going from here?
Up
Flat
Down
Stock chart of ETTX
Analysts
Summary of analysts' recommendations for ETTX
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Entasis Therapeutics Holdings Inc. produces, researches and develops antibacterial therapies and drugs through its subsidiaries. The company's product pipeline consists of etx2514sul, zoliflodacin, etx0282cpdp and nbp program which are in clinical stage. Entasis Therapeutics Holdings, Inc. is based in Waltham, Massachusetts.